These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 17948599)

  • 1. Mixed co-receptor use associated with lower CD4 count.
    Morris K; Alcorn K
    IAPAC Mon; 2007 Feb; 13(2):38-9. PubMed ID: 17948599
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Coreceptors for HIV-1 infection].
    Yu Z; Qin J
    Wei Sheng Wu Xue Bao; 1998 Feb; 38(1):78-80. PubMed ID: 12549394
    [No Abstract]   [Full Text] [Related]  

  • 4. [HIV infection, chemokines and other receptors].
    Bracco MM; Ruibal-Ares B
    Medicina (B Aires); 2000; 60(4):525-6. PubMed ID: 11188963
    [No Abstract]   [Full Text] [Related]  

  • 5. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen.
    Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G
    Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 tropism, disease progression, and clinical management.
    Burger H; Hoover D
    J Infect Dis; 2008 Oct; 198(8):1095-7. PubMed ID: 18783314
    [No Abstract]   [Full Text] [Related]  

  • 7. Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians.
    Dubey S; Khalid M; Wesley C; Khan SA; Wanchu A; Jameel S
    J Clin Virol; 2008 Sep; 43(1):25-31. PubMed ID: 18462992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human immunodeficiency virus. New aspects of pathogenesis].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 1998 Jul; 21(7):214-6. PubMed ID: 9735013
    [No Abstract]   [Full Text] [Related]  

  • 9. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
    Soulié C; Marcelin AG; Ghosn J; Amellal B; Assoumou L; Lambert S; Duvivier C; Costagliola D; Katlama C; Calvez V
    AIDS; 2007 Oct; 21(16):2243-5. PubMed ID: 18090053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of chemokine receptors on natural killer cells in HIV-infected individuals.
    Jiang Y; Zhang Z; Diao Y; Jin X; Shi W; Geng W; Dai D; Zhang M; Han X; Liu J; Wang Y; Shang H
    Cell Immunol; 2008 Jan; 251(1):19-24. PubMed ID: 18359010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the thymus in HIV infection: a 10 year perspective.
    Ho Tsong Fang R; Colantonio AD; Uittenbogaart CH
    AIDS; 2008 Jan; 22(2):171-84. PubMed ID: 18097219
    [No Abstract]   [Full Text] [Related]  

  • 12. Getting personal about treating HIV.
    Neaton JD; Lane HC
    Nat Med; 2008 Apr; 14(4):369-70. PubMed ID: 18391933
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-HIV agents. Receptor blocker (SCH 532706) enters clinical trials.
    TreatmentUpdate; 2008 Mar; 20(2):8-9. PubMed ID: 18663778
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.
    Dolan MJ; Kulkarni H; Camargo JF; He W; Smith A; Anaya JM; Miura T; Hecht FM; Mamtani M; Pereyra F; Marconi V; Mangano A; Sen L; Bologna R; Clark RA; Anderson SA; Delmar J; O'Connell RJ; Lloyd A; Martin J; Ahuja SS; Agan BK; Walker BD; Deeks SG; Ahuja SK
    Nat Immunol; 2007 Dec; 8(12):1324-36. PubMed ID: 17952079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients.
    Pett SL; McCarthy MC; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki JM; Williams KM; Emery S
    Antivir Ther; 2009; 14(1):111-5. PubMed ID: 19320244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years.
    Briz V; Poveda E; López M; González Mdel M; Soriano V; Benito JM
    AIDS; 2008 Jul; 22(11):1371-4. PubMed ID: 18580618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
    Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
    J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of chemokine receptor expression in aggressive NK-cell leukemia and chronic NK-cell lymphocytosis].
    Makishima H
    Rinsho Ketsueki; 2008 Jan; 49(1):3-9. PubMed ID: 18277590
    [No Abstract]   [Full Text] [Related]  

  • 20. Type C coping, alexithymia, and heart rate reactivity are associated independently and differentially with specific immune mechanisms linked to HIV progression.
    Temoshok LR; Waldstein SR; Wald RL; Garzino-Demo A; Synowski SJ; Sun L; Wiley JA
    Brain Behav Immun; 2008 Jul; 22(5):781-92. PubMed ID: 18346864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.